Skip to main content

Table 5 Expression of RND efflux systems, amino acid substitutions in regulatory genes and antimicrobial susceptibility pattern of 15 A. baumannii isolates with more than four-fold reduction in MIC of at least one antibiotic

From: Characteristics and diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with drug-resistant clinical isolates of Acinetobacter baumannii

Strain Ward of isolation Expression level Amino acid substitutions AST pattern AST pattern without PAβN (µg/ml)/fold reduction in MIC with PAβN
adeB adeG adeJ AdeR AdeS AdeL AdeN BaeS BaeR IMP LVX FEP TGC GEN
ATCC 19,606 1 1 1
M2 ICU 2.47 2.53 1.24 H158L L172P,H189Y,R195G,V235I,S280A,Q281D,Y303F Q262R S471N,P474S S40N XDR R(32)/– R(32)/– R(256)/6 R(8)/– R(128)/4
M3 ICU 2.56 8.75 2.51 H158L L172P,H189Y,R195G,V235I,S280A,Q281D,Y303F Q262R S471N,P474S S40N XDR R(32)/– R(12)/– R(256)/6 R(12)/– R(256)/7
M4 ICU 1.97 0.26 2.11 H158L L172P,H189Y,R195G,V235I,S280A,Q281D,Y303F Q262R S471N,P474S S40N XDR R(32)/– R(32)/– R(256)/6 R(8)/– R(256)/5
M9 ICU 10.70 32.89 2.63 I120V,A136V L172P,G186V,N268H,S280A,Q281D,Y303F S437T XDR R(32)/– R(32)/4 R(256)/4 R(8)/– R(256)/6
M20 ICU 9.31 0.09 2.86 D93E, I120V,F132S S46N, L172P, F214L,I257V,S280A,Q281D,Y303F,I331V S471N XDR R(32)/– I(4)/– R(64)/– R(8)/5 R(256)/–
M23 ICU 10.99 0.04 0.90 D93E, I120V,F132S S46N, L172P, F214L,I257V, S280A,Q281D, Y303F S471N XDR R(32)/– I(4)/– R(256)/4 R(12)/6 R(256)/–
M24 ICU 5.27 3.89 5.85 I120V,A136V L172P,G186V,N268H,S280A,Q281D,Y303F,N342I S437T XDR R(16)/– R(8)/– R(64)/– R(16)/6 R(16)/–
M29 ICU 1.21 0.008 0.99 D93E, I120V,F132S S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V S471N XDR R(32)/– R(12)/– R(192)/– R(12)/5 R(256)/–
M30 ICU 1.74 0.002 1.85 D93E, I120V,F132S S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,N342I S471N XDR R(32)/– I(4)/– R(96)/– R(8)/5 R(256)/–
M31 ICU 0.53 0.22 1.82 H158L L172P,H189Y,R195G,S280A,Q281D,Y303F,V235I Q262R S471N,P474S S40N XDR R(32)/– R(16)/– R(256)/5 R(16)/– R(96)/–
M40 ICU 19.69 0.90 2.04 L172P,F214L, S280A,Q281D,Y303F Q262R S471N,P474S S40N XDR R(32)/– R(8)/– R(64)/– R(8)/– R(256)/–
M42 ICU 16.44 42.51 2.02 L172P,F214L, S280A,Q281D,Y303F Q262R S471N,P474S S40N XDR R(32)/– R(8)/– R(64)/– R(8)/– R(256)/–
M54 ICU 1.10 0.001 1.75 D93E, I120V,F132S S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V, N342I XDR R(32)/– I(4)/– R(256)/5 S(2)/– R(256)/–
M59 ICU 5.09 0.004 0.82 D93E, I120V,F132S S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V, N342I S471N XDR R(32)/– I(4)/– R(256)/5 R(8)/4 R(256)/–
M60 ICU 1.16 0.70 1.74 D93E, I120V,F132S S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V, N342I S471N XDR R(32)/– R(32)/– R(256)/– I(4)/– R(256)/5
  1. AST, antimicrobial susceptibility testing; PAβN, phenylalanine-arginine beta-naphthylamide; MIC, minimum inhibitory concentration; IMP, imipenem; LVX, levofloxacin; FEP, cefepime; TGC, tigecycline; GEN, gentamicin